Klotho Neurosciences (KLTO)announced that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. platform technology.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences seeking to expand into adjacent technologies
- Klotho Neurosciences Partners with AAVnerGene for Gene Therapy
- Klotho Neurosciences partners with AAVnerGene to make gene therapy assets
- Klotho Neurosciences Regains Nasdaq Compliance
- Klotho Neurosciences regains compliance with Nasdaq